Stopping rules, interim analyses and data monitoring committees
1993
Stopping Rules and Data Monitoring in Cancer Trials
Editorial
Author Information
Author(s): D. Ashby, D. Machin
Primary Institution: The University of Liverpool; MRC Cancer Trials Office
Conclusion
The editorial emphasizes the importance of data monitoring committees in clinical trials to ensure ethical considerations and accurate results.
Supporting Evidence
- Many cancer trials stop early due to ethical concerns about patient safety.
- Data monitoring committees are essential for making informed decisions about trial continuation.
- Most trials do not adequately report their intended sample sizes or stopping rules.
Takeaway
When testing new cancer treatments, it's important to have rules about when to stop the trial if the treatment isn't working, to protect patients and get clear results.
Potential Biases
Potential bias may arise from the ethical dilemma of stopping trials early based on interim results.
Limitations
Many trials do not report intended sample sizes or stopping rules, which complicates the interpretation of results.
Want to read the original?
Access the complete publication on the publisher's website